melanoma
Showing NaN - NaN of 85
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified
Recruiting
- Endometrial Cancer
- +8 more
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
-
Orlando, Florida
- +21 more
Feb 2, 2023
Solid Tumor, Non Small Cell Lung Cancer, Melanoma Trial in Lafayette, Boston, Nashville (AB248, Pembrolizumab)
Recruiting
- Solid Tumor
- +4 more
- AB248
- Pembrolizumab
-
Lafayette, Indiana
- +2 more
Jan 25, 2023
Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC Trial in Australia, United States (RO7502175, Atezolizumab)
Recruiting
- Locally Advanced or Metastatic Solid Tumors
- +10 more
-
Aurora, Colorado
- +6 more
Jan 4, 2023
Malignant Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) Trial in Worldwide (GEN1042, Pembrolizumab,
Recruiting
- Malignant Solid Tumor
- +5 more
- GEN1042
- +8 more
-
San Diego, California
- +27 more
Dec 24, 2022
Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)
Active, not recruiting
- Melanoma
- +7 more
- Autogene cevumeran
- Atezolizumab
-
Scottsdale, Arizona
- +36 more
Dec 22, 2022
Small Cell Lung Cancer, NSCLC, Squamous, NSCLC, Non-squamous Trial in Worldwide (ladiratuzumab vedotin)
Recruiting
- Small Cell Lung Cancer
- +8 more
- ladiratuzumab vedotin
- pembrolizumab
-
Chandler, Arizona
- +65 more
Dec 19, 2022
Melanoma Trial in Worldwide (Dabrafenib, Trametinib, Placebos)
Will Permit Sites to Proactively Assess TAA, HLA and HPV-16
Terminated
- Head and Neck Cancer
- +7 more
- Tumor Profiling
-
Scottsdale, Arizona
- +2 more
Dec 2, 2022
Melanoma Trial in Worldwide (Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination)
Recruiting
- Melanoma
- Nivolumab
- Nivolumab + Relatlimab Fixed Dose Combination
-
Birmingham, Alabama
- +185 more
Dec 3, 2022
Melanoma, Prostate Cancer, Ovarian Cancer Trial in United States (Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or
Active, not recruiting
- Melanoma
- +8 more
- Pegilodecakin
- +9 more
-
Los Angeles, California
- +9 more
Nov 15, 2022
Melanoma Trial in Worldwide (Talimogene Laherparepvec, Pembrolizumab, Placebo)
Terminated
- Melanoma
- Talimogene Laherparepvec
- +2 more
-
Birmingham, Alabama
- +160 more
Nov 10, 2022
Squamous Cell Carcinoma of Head and Neck, NSCLC, Hepatocellular Carcinoma Trial in Worldwide (KY1044, KY1044 and atezolizumab)
Recruiting
- Squamous Cell Carcinoma of Head and Neck
- +11 more
- KY1044
- KY1044 and atezolizumab
-
New Haven, Connecticut
- +12 more
Nov 3, 2022
Predict Recurrence and Response to Systemic Therapy
Recruiting
- Melanoma
- Blood draw (before surgery)
- +2 more
-
Nashville, TennesseeVanderbilt-Ingram Cancer Center
Nov 2, 2022
Breast Cancer, Colorectal Cancer, Ovarian Cancer Trial in United States (ATRC-101, Pembrolizumab, Pegylated liposomal
Recruiting
- Breast Cancer
- +15 more
- ATRC-101
- +2 more
-
Phoenix, Arizona
- +10 more
Sep 28, 2022
NSCLC, Melanoma Trial in Worldwide (LXH254, LTT462, Trametinib)
Active, not recruiting
- Non-Small Cell Lung Cancer
- Melanoma
- LXH254
- +3 more
-
San Diego, California
- +31 more
Sep 12, 2022
Melanoma Trial in Australia, United States (mRNA-4157, Pembrolizumab)
Active, not recruiting
- Melanoma
- mRNA-4157
- Pembrolizumab
-
Tucson, Arizona
- +21 more
Aug 23, 2022
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Urinary Bladder Cancer, Melanoma, Head Neck Cancer Trial in Canada, United States (Autologous genetically modified MAGE-A4?¹º³²T
Active, not recruiting
- Urinary Bladder Cancer
- +9 more
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
- Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
-
Miami, Florida
- +10 more
Aug 9, 2022